Find disease awareness content and relevant supporting materials
Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion ...
Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI
Antiplatelet therapy is one of the cornerstones in the acute treatment of patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI).
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization
The primary objective of this study is to evaluate the efficacy of ranolazine as compared with placebo when used as...
FDA approves the Onyx Frontier drug-eluting stent (DES) and the Resolute Onyx DES to treat bifurcation percutaneous coronary intervention
Medtronic announced that it has received FDA approval for the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique (using a single stent to treat the bifurcation) with the Onyx Frontier drug-eluting stent (DES) and the Resolute Onyx DES
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents remains uncertain. We compared short-term (<6-month) DAPT followed by aspirin or P2Y12 inhibitor monotherapy; midterm (6-month) DAPT; 12-month DAPT; and extended-term (>12-month) DAPT after percutaneous coronary intervention with drug-eluting stents.